Clinical Scorecard: FDA approves quarterly siRNA for myasthenia gravis
At a Glance
| Category | Detail |
|---|---|
| Condition | Clinical topic addressed by the source article: FDA approves quarterly siRNA for myasthenia gravis |
| Key Mechanisms | Mechanisms or clinical associations described in the source article. |
| Target Population | Population described in the source article. |
| Care Setting | Cemdisiran is administered subcutaneously by a health care provider every 3 months and is available only through a restricted Risk Evaluation and Mitigation Strategy (REMS) program. |
Key Highlights
- Cemdisiran (Livsayis) is the first siRNA therapy approved for gMG and the only FDA-approved gMG treatment with quarterly subcutaneous dosing, according to the company.
- In the phase 3 NIMBLE trial primary analysis population, the week-24 MG-ADL score improved by 4.5 points with cemdisiran and 2.2 points with placebo; the placebo-adjusted difference was 2.3 points.
- At least a 3-point MG-ADL improvement occurred in 76.6% of cemdisiran-treated patients and 44.1% of placebo-treated patients.
- QMG scores improved by 4.2 points with cemdisiran and 1.5 points with placebo; the placebo-adjusted improvement was 2.8 points. At least a 5-point QMG improvement occurred in 48.4% and 19% of patients, respectively.
- Regeneron reported improvements beginning within 2 weeks and maintained through 24 weeks.
- The prescribing information includes a boxed warning for serious meningococcal infections and requires access through a restricted REMS program.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
- The prescribing information warns about serious meningococcal infection and other serious infections associated with reduced complement activity.
- Reported adverse reactions included injection-site reactions, viral infections, and urinary tract infections.
Risks
Patient & Prescribing Data
Cemdisiran is given at 567 mg subcutaneously every 3 months by a health care provider. FDA approval was supported by the randomized, double-blind, placebo-controlled phase 3 NIMBLE trial of 284 patients, which evaluated cemdisiran alone, a C5-inhibiting monoclonal antibody alone, the combination, or placebo.
Clinical Best Practices
- Confirm meningococcal vaccination is up to date and given at least 2 weeks before treatment when possible.
- Use antibacterial prophylaxis when urgent treatment is required and the patient is not up to date with meningococcal vaccination.
- Follow the restricted REMS program and do not initiate treatment during an unresolved serious Neisseria meningitidis infection.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
